IMV IMV Inc.

3.45
+0.09  (+3%)
Previous Close 3.36
Open 3.41
Price To Book 57.5
Market Cap 174560706
Shares 50,597,306
Volume 9,761
Short Ratio
Av. Daily Volume 38,753

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due at ICML meeting June 9-15, 2019.
DPX-Survivac and pembrolizumab
Diffuse Large Cell Lymphoma
Phase 2 monotherapy and combo data due at ASCO June 1, 2019, 1:15pm CT.
DPX-Survivac and epacadostat
Ovarian cancer
Phase 2 trial ongoing.
DPX-Survivac and pembrolizumab
Ovarian cancer
Phase 2 preliminary data due 2H 2019, with top-line data due 1H 2020.
DPX-Survivac and KEYTRUDA (pembrolizumab) - basket trial
Solid tumors
Phase 1 dosing has commenced - January 17, 2019.
DPX-NEO - neoepitopes
Ovarian cancer

Latest News

  1. IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors
  2. IMV Inc. Issues Statement on Recent Market Activity And Provides Corporate Update
  3. IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Conference; Announces Update to Presentation at H.C. Wainwright Investor Conference
  4. New Preclinical Research Presented at AACR 2019 Reveals Unique Anti-Cancer Mechanism of Action Underscoring IMV’s Immunotherapy Program
  5. Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer
  6. IMV Inc. to Present at Two Upcoming Investor Conferences
  7. IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs
  8. IMV and Centre de Recherche du CHU de Québec-Université Laval Collaboration Awarded a CQDM Grant to Develop First-in-Class Dual Target T Cell Therapy in Bladder Cancer Based on IMV’s DPX Technology
  9. IMV Researchers to Present New Preclinical Data at AACR Annual Meeting 2019
  10. IMV Inc. Announces Partial Exercise of Option To Purchase Additional Shares in Connection with Underwritten Public Offering of Common Shares
  11. IMV Inc. to Announce 2018 Fourth Quarter and Fiscal Year-End Results and Host Investor Conference Call and Webcast on March 22, 2019
  12. IMV Inc. to Present at the Cowen and Company 39th Annual Health Care Conference
  13. IMV Inc. Closes Previously Announced Public Offering
  14. IMV Inc. Announces Pricing of Public Offering
  15. IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
  16. IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA
  17. IMV to Present at 2019 BIO CEO & Investor Conference
  18. First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients
  19. IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress
  20. IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac’s Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018